

REPUBLIC OF THE PHILIPPINES DEPARTMENT OF FINANCE BUREAU OF INTERNAL REVENUE



JUN 2 0 2025

REVENUE MEMORANDUM CIRCULAR NO. 062-2025

SUBJECT: Publishing the Full Text of the May 15, 2025 Letter from the Food and Drug

Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Products Under Republic Act (R.A.)

No. 10963 (TRAIN Law) and R.A. No. 11534 (CREATE Act)


TO: All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the May 15, 2025 letter (Annex "A") from Atty. Paolo S. Teston, Director General of the FDA, for an update to the published List of VAT-Exempt Medicines under R.A. No. 11534 or the CREATE Act, particularly the following:

- 1. Inclusion of certain medicines for cancer, diabetes, high cholesterol, hypertension, and mental diseases tuberculosis; and
- 2. Deletion of certain medicine for cancer.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.

All concerned are hereby enjoined to be guided accordingly and give this Circular as wide a publicity as possible.





ROMEO D. LUMAGUI, JR.
Commissioner of Internal Revenue